Embryonic endothelial progenitor cells armed with a suicide gene target hypoxic lung metastases after intravenous delivery  by Wei, Jiwu et al.
A R T I C L E
Embryonic endothelial progenitor cells armed with a suicide
gene target hypoxic lung metastases after
intravenous delivery
Jiwu Wei,1 Sabine Blum,2 Marcus Unger,1 Gergely Jarmy,1 Mathias Lamparter,2 Albert Geishauser,2
Georgios A. Vlastos,2 Gordon Chan,3 Klaus-Dieter Fischer,3 Dirk Rattat,4 Klaus-Michael Debatin,1
Antonis K. Hatzopoulos,2,* and Christian Beltinger1,*
1University Children’s Hospital, Ulm D-89075, Germany
2 GSF-National Research Center for Environment and Health, Munich D-81377, Germany
3 Department of Physiological Chemistry
4 Department of Nuclear Medicine
University of Ulm, Ulm D-89081, Germany
*Correspondence: christian.beltinger@medizin.uni-ulm.de (C.B.), hatzopoulos@gsf.de (A.K.H.)
Summary
We show that mouse embryonic endothelial progenitor cells (eEPCs) home preferentially to hypoxic lung metastases when
administered intravenously. This specificity is inversely related to the degree of perfusion and vascular density in the
metastasis and directly related to local levels of hypoxia and VEGF. Ex vivo expanded eEPCs that were genetically modified
with a suicide gene specifically and efficiently eradicated lung metastases with scant patent blood vessels. eEPCs do not
express MHC I proteins, are resistant to natural killer cell-mediated cytolysis, and can contribute to tumor vessel formation
also in nonsyngeneic mice. These results indicate that eEPCs can be used in an allogeneic setting to treat hypoxic
metastases that are known to be resistant to conventional therapeutic regimes.
Introduction (Gomez-Navarro et al., 2000). These findings offer the possibility
to exploit EPCs for cancer therapy (Asahara et al., 1999). How-
The growth and metastasis of solid tumors correlate with their ever, the utility of bona fide, ex vivo expanded EPCs for this
ability to induce formation of new blood vessels. In addition to purpose without prior bone marrow transplant is yet unknown.
sprouting angiogenesis from neighboring resident endothelial The potential of eEPCs to serve as cellular vehicles to target
cells, tumors also build vessels by recruitment and in situ differ- cancers depends on efficient and specific (ex vivo) gene transfer
entiation of circulating endothelial progenitor cells (Hanahan and the ability to stably carry therapeutic loads through the
and Folkman, 1996; Asahara et al., 1997, 1999; Shi et al., 1998; blood stream to the intended target. What renders EPCs an
attractive candidate cellular vehicle is that they may home exclu-Peichev et al., 2000; Gehling et al., 2000; Lyden et al., 2001;
Reyes et al., 2002). Bone marrow-derived endothelial precursors sively to sites of active neovasculogenesis. Because cancers
most often kill by metastases, it is crucial to evaluate the efficacyare necessary and sufficient for tumor angiogenesis (Lyden et
al., 2001), and EPCs differentiated ex vivo from multipotent adult of EPCs for cancer therapy in metastatic models. Thus, knowl-
edge of the differential homing of EPCs to metastases of differ-progenitor cells home to tumors (Reyes et al., 2002). Irradiation
followed by bone marrow transplantation of unfractionated bone ent size, in different organs, in different locations within a tissue,
as well as to normal organs, is essential, but not available.marrow cells (Davidoff et al., 2001), endothelial progenitor-like
cells (Ferrari et al., 2003), or tie-2 myeloid progenitors (De The study of adult endothelial progenitor cells is in early
stages and under intense debate (Rafii and Lyden, 2003; Pat-Palma et al., 2003), which were engineered to hinder angiogen-
esis, slows growth of posttransplant tumor challenges. Geneti- terson, 2003). Adult stem cells are difficult to isolate and main-
tain in vitro, which diminishes availability and thus the prospectscally modified CD34 cells also homed to angiogenic sites in
a rhesus monkey model and exerted a bystander effect in vitro of systematic molecular studies and genetic manipulation. One
S I G N I F I C A N C E
The contribution of endothelial progenitor cells to tumor neoangiogenesis opens new ways to hinder tumor growth. We found that
embryonic endothelial progenitor cells (eEPCs) show a remarkably efficient and specific affinity for disseminated lung metastases
without the need of prior irradiation and bone marrow transplantation. They particularly targeted hypoxic lung metastases that are
often resistant to chemotherapy or radiation therapy. Homing of eEPCs to normal tissues was low and without adverse effects or
formation of teratocarcinomas. eEPCs can be expanded indefinitely, are easy to manipulate ex vivo, and appear to be immunoprivi-
leged. Taken together, these results suggest that embryonic EPCs constitute clinically relevant cellular vehicles for systemic gene
therapy of lung metastases.
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exciting alternative are the embryonic endothelial progenitor planted subcutaneously into C3H mice. This experimental
setup, as compared to intravenous (i.v.) injection of eEPCs intocells (eEPCs) isolated from mouse embryos or derived from
differentiation of embryonic stem cells (Hatzopoulos et al., 1998; tumor-bearing mice, allowed longer observation periods and
increased the number of eEPCs contributing to blood vesselLevenberg et al., 2002; Yurugi-Kobayashi et al., 2003; Marchetti
et al., 2002). Embryonic EPCs possess distinct advantages: they formation, thus facilitating evaluation of eEPC survival. Tumor
growth was followed for up to 24 days before FITC-labeled HPAgrow in unlimited fashion, proliferate rapidly, and are easily
amenable to genetic manipulation (Hatzopoulos et al., 1998). It lectin was injected intravenously to decorate tumor vessels 5
min prior to tumor isolation. Tumors were examined by whole-was recently shown that embryonic EPCs retain their ability to
incorporate into vascular networks in active sites of angiogen- mount fluorescence microscopy. Nearly all eEPCs in the visible
tumor periphery had incorporated into tumor vessels, and 20%–esis in the adult (Yurugi-Kobayashi et al., 2003; Vajkoczy et al.,
2003). It is yet unknown, though, whether eEPCs possess a 25% of the tumor vasculature was composed of DiI-positive
eEPC-derived cells (Figure 1D), indicating that eEPCs survivedifferent therapeutic potential than adult EPCs. Based on these
properties, we investigated the homing and therapeutic utility and build tumor vessels in nonsyngeneic hosts.
of mouse eEPCs armed with a suicide gene in syngeneic and
nonsyngeneic lung metastasis models without bone marrow Tail vein-injected eEPCs are sequestered mainly
in the lung and spleentransplantation.
The effectiveness of eEPCs as a cellular vehicle for tumor ther-
apy depends on normal tissue being spared by eEPCs. WeResults
therefore quantitatively determined the distribution and fate of
eEPCs in various organs of tumor-free mice after tail vein injec-eEPCs do not express MHC I, are resistant against
nonactivated NK cells, and form tumor vessels tion of cells loaded with 111Indium (In)-labeled low-density lipo-
protein (LDL). The efficacy of LDL-particle uptake by eEPCsin nonsyngeneic mice
An advantage for cell-based therapeutic approaches would be was assessed in parallel experiments using DiI-labeled LDL.
DiI-labeled LDL was readily and uniformly taken up and retaineddonor material that is not rejected by the host’s immune system.
Cells isolated from early embryonic stages such as the eEPCs by eEPCs. Similarly, there was no leakage of radioactive label
into the medium after 48 hr of cell culture of eEPCs labeled withmight possess such properties, because early embryonic tissue
evades the maternal immune system until the immunological 111In-LDL, and the radioactive labeling did not affect cellular
morphology or proliferation rates (data not shown). Cell-freebarrier between mother and fetus is established. Therefore, we
examined whether the eEPCs isolated at E7.5 possess molecu- 111In-labeled LDL is taken up predominantly by the liver (Virgolini
et al., 1991), whereas small fragments of 111In-DTPA (diethylene-lar features that allow them to evade rejection when transplanted
in nonsyngeneic mice. triaminepenta-acetic acid)-LDL and 111In-DTPA are excreted by
the kidneys (Rogers et al., 1995). Thus, except for liver andMHC I surface antigens determine the response of cytotoxic
T cells against allogeneic cells. We determined the level of MHC kidneys, radioactivity in organs represented the presence of
eEPCs.I expression on eEPCs using a pan anti-MHC class I antibody.
FACS analysis indicated that MHC I antigens were not ex- After tail vein injection into C3H mice, eEPCs were seques-
tered predominantly in the lung and the spleen (Figure 2A).pressed on three eEPC clones isolated independently from
C57BL/6 mice, whereas control fibroblasts, T cells, and mast Sequestration of eEPCs in liver and kidneys was low, consider-
ing that activity in these organs may also represent label beingcells from this strain showed strong antibody binding (Figure
1A). This result suggests that eEPCs are protected against T cell- excreted. There were no measurable counts in gut, brain, empty
bladder, bone, or bone marrow. Organ-specific radioactivitymediated immune responses.
Because rejection of transplants is also determined by sensi- decreased over time, and radioactivity was detected in the cage
bedding consistent with sequestered eEPCs being destroyedtivity toward NK cells, we tested whether NK cells can target
the MHC I-negative eEPCs. To assess spontaneous NK cell and cell-free label being excreted into urine and stool.
We confirmed and extended the biodistribution data by im-cytotoxicity against eEPCs, we performed cell lysis assays using
T cell-depleted splenocytes derived from C3H mice. As positive munohistochemistry analysis. eEPCs marked with enhanced
green fluorescent protein (EGFP) were present in low numbersand negative controls, we used YAC-1 and RMA/S, respectively,
as target cell lines. YAC-1 cells are derived from A/Sn mice and in the lung and spleen of C3H mice while rare eEPCs were
detected in liver and brain and no eEPCs were found in theare sensitive to C3H-derived NK cell-mediated spontaneous
cytotoxicity. In contrast, the MHC class I-deficient RMA/S cells, kidneys and in the bone marrow (Figure 2B and data not shown).
Taken together, these data show that sequestration leads to aderived from C57BL/6 mice, are resistant. We found that YAC-1
cells were readily lysed in the presence of freshly isolated NK low-density distribution of tail vein-injected eEPCs predomi-
effectors, while eEPCs were resistant to NK cells similar to nantly in lung and spleen that diminishes over time.
RMA/S cells, suggesting that eEPCs do not engage activating
NK receptors (Figure 1B). The escape of early surveillance by Tail vein-injected eEPCs home specifically
and efficiently to metastases in the lungNK cells coupled to the lack of MHC I antigens may allow
recruitment and persistence of eEPCs in nonsyngeneic hosts. Next we wanted to know whether eEPCs home to tumors and
which tumor characteristics influence homing. We investigatedTo test this notion, LM8 osteosarcoma cells (which are de-
rived from C3H mice of H-2Kk haplotype) were mixed with DiI the homing of eEPCs in two mouse models of multiple metasta-
ses using the LM8 osteosarcoma cell line that creates metasta-(1,1-dioctadecyl-3,3,33-tetramethylindocarbocyanine per-
chlorate)-labeled eEPCs from 129Sv, C57/BL/6, or FVB mice ses in lung, liver, and kidneys and the Lewis lung carcinoma
(LLC) cells that form metastases only in the lung. We injected(H-2Kb, H-2Kb, and H-2Kq haplotypes, respectively) and trans-
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Figure 1. eEPCs are immunoprivileged
A: FACS analysis using a pan anti-mouse MHC I antibody shows no MHC I expression in three independently isolated eEPC clones, F19B, T15B, and T14B.
NIH 3T3 fibroblasts, T cells, and primary mouse mast cells display high MHC I levels and were used as positive controls.
B: eEPCs are resistant to nonactivated NK cells. Freshly purified splenocytes depleted of CD4 and CD8 cells were used as effectors (E) in a standard 51Cr-
release assay against the following target cells (T): YAC-1 (sensitive to spontaneous NK cells), RMA/S (resistant to NK cells), and TI5B (an eEPC cell line).
Results are representative of two independent experiments.
C and D: eEPCs form tumor vessels in nonsyngeneic mice. DiI-labeled eEPCs from C57/BL/6 mice were subcutaneously cotransplanted with LM8 cells in a
ratio of 1:20 into C3H mice. After 24 days of tumor growth, mice were injected i.v. with HPA-FITC-lectin to decorate perfused tumor vessels before tissue
isolation. Whole-mount tumor specimens were examined by fluorescence microscopy. Arrows point to the same areas for orientation. Scale bars represent
150 m.
C: HPA-FITC-lectin decorated tumor vessels (green color).
D: Incorporation of DiI-labeled eEPCs (orange) into the tumor vasculature (green).
LM8 cells by tail vein injection in C3H mice (syngeneic to LM8 in the lung showed similar results (Figure 3F). In both tumor
types, homing was specific within the metastases, since verycells) and LLC cells in C57BL/6 mice (syngeneic to LLC cells).
Fourteen days later, we transplanted into both tumor models few eEPCs were found in the surrounding normal lung tissue
at this time point (Figures 3A–3F). Homing was also efficienteEPCs isolated from C57BL/6 E7.5 embryos and marked either
by DiI or by stable EGFP expression. Consequently, the eEPCs with numerous eEPCs present within the tumor nodules.
To further quantify eEPC homing, the lungs of six micewere syngeneic in the LLC-carrying mice and allogeneic in the
LM8-bearing mice. with LM8 metastases, which received EGFP-transfected eEPCs
twice spaced 3 days apart, were sectioned in 4 M intervalsFive to seven days after tail vein injection of DiI-labeled
eEPCs or eEPCs expressing EGFP in mice with LM8 metastases and the presence of eEPCs was determined by immunohisto-
chemistry using an antibody against EGFP. eEPCs were foundin the lung, liver, and kidneys, histological analysis showed that
eEPCs homed into most metastases in the lung (Figures 3A–3D) in 77% of all lung metastases with a range of 67% to 100%
(see Supplemental Table S1 at http://www.cancercell.org/cgi/and with low frequency into liver and kidney metastases (Figure
3E). Thus, when given via the tail vein, eEPCs appear to home content/full/5/5/477/DC1). eEPCs were also present in 2 out
of 17 liver metastases and in 1 out of 6 kidney metastases.to lung metastases in a first pass effect but far less efficiently
to metastases downstream of the lung. Experiments in three mice carrying LLC tumors in the lung
showed homing to 90% of the metastases.Parallel experiments using mice carrying LLC metastases
CANCER CELL : MAY 2004 479
A R T I C L E
Figure 2. Transient and low-level distribution of eEPCs in normal organs fol-
lowing tail vein injection
A: 111In-LDL-labeled eEPCs were injected into the tail vein of C3H mice and
organs were procured and analyzed using a  counter on days 2 (n  3)
and 5 (n  3) after injection. Background activity was subtracted, and
organ-specific levels of radioactivity were calculated as activity per mg of
organ mass. The means and standard deviations are depicted. Similar results
were obtained in two independent experiments.
B: EGFP-labeled eEPCs were injected into the tail vein of C3H mice. Organs
were isolated 2 days later and eEPCs were detected by immunohistochem-
istry using an anti-EGFP antibody (brown staining) in lung and spleen. Scale
bars represent 50 m.
Taken together, homing in lung metastases was indepen-
dent of the eEPC labeling technique, the tumor type, and the
location of the metastases in the lung, and it was comparable in Figure 3. Tail vein-injected eEPCs specifically home to metastases mainly in
the lungboth syngeneic and nonsyngeneic mice. To exclude unspecific
LM8 or LLC cells were injected into the tail vein of C3H or C57/BL/6 mice,sequestration as a major cause of eEPC delivery to the metasta-
respectively. After metastases had formed, DiI- or EGFP-labeled eEPCs orses, we performed parallel experiments with DiI-labeled fibro-
fibroblasts were injected i.v. Following organ procurement, the injectedblasts, which are of similar size as the eEPCs (20–25 M).
cells were detected by DiI fluorescence or by immunohistochemistry using
Histological examination of lung tissue of LLC-bearing mice 2 an anti-EGFP antibody.
days after i.v. cell injection showed that similar numbers of A and B: DiI-labeled eEPCs home to LM8 lung metastases. Organs were
secured 7 days after injection of eEPCs. Numerous eEPCs are present ineEPCs and fibroblasts were present within normal lung tissue.
subpleural metastases (M) but not within adjacent lung tissue (L).In contrast, we observed no or only occasional fibroblasts within
C and D: EGFP-labeled eEPCs home to LM8 lung metastases. eEPCs were
tumor nodules, whereas at the same time point there was an injected i.v. twice spaced 3 days apart and organs were secured 5 days
abundance of tumor-embedded eEPCs (Figures 3G–3J). Thus, later. Numerous eEPCs (brown staining) are seen in a metastasis but not in
adjacent normal tissue. D is a higher magnification of C.while sequestration in the lung was comparable for both cell
E: Low numbers of eEPCs (brown staining; arrows) home to LM8 metastasestypes, efficient homing to metastases was a specific property
in liver tissue of mice generated as described in C and D.of eEPCs. F: EGFP-labeled eEPCs home to LLC lung metastases. Mice received two
injections of eEPCs spaced 3 days apart and lungs were procured 5 days
later. eEPCs home to LLC metastases in the lung (M, arrows) but not toLung metastases with impaired vascular function
adjacent lung tissue (L).preferentially recruit eEPCs
G–J: Fibroblasts do not home to LLC metastases. Mice were injected onceWe observed that in both the LM8 and LLC tumor models, not with DiI-labeled fibroblasts or eEPCs and lungs were retrieved 2 days later.
all metastases in the lung recruited eEPCs (Figures 4A and No fibroblasts are seen in the metastases, while some are found in the lung
parenchyma (G and H; arrows point to the same area for orientation). In4B). We therefore examined whether size, vascular density, and
contrast, numerous eEPCs have homed into a metastasis (I and J; the insidelocalization of the metastases influence homing of eEPCs.
of a large metastasis is depicted). G and I are H&E stains.Histological analysis of recruiting and nonrecruiting large
Scale bars represent 200 m (A–C, F–J) and 50 m (D and E).
LM8 tumor nodules localized in subpleural areas showed that
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Figure 4. Lung metastases with impaired vascu-
lar function preferentially recruit eEPCs
A–H: LM8 cells were injected into the tail vein
of C3H mice, and DiI-labeled eEPCs were given
once by tail vein 14 days later. Seven days later,
organs were retrieved and cryosectioned for
fluorescence microscopy to visualize the DiI-
labeled cells.
A–C: eEPCs preferentially home to poorly per-
fused metastases. Five to seven minutes before
organ isolation, HPA-FITC-labeled lectin was in-
jected i.v. to decorate perfused blood vessels.
Phase contrast microscopy of lung sections (A)
shows two adjacent metastases (Met1 and
Met2) separated by pleural lining (arrows). Fluo-
rescence microscopy revealed homing of DiI-
labeled eEPCs into Met1 only (B), correlating with
less perfused tumor vessels as visualized by bind-
ing of HPA-FITC lectin to endothelial cells (C).
D–F: Phase contrast microscopy (D) delineates
the two adjacent metastases Met1 and Met2
(the pleural demarcation is outlined by arrow-
heads). DiI-labeled eEPCs are present only in
Met1 (E) that is less vascularized as shown by
anti-collagen IV antibody labeling (F).
G and H: Metastases recruiting eEPCs show high
VEGF expression. LM8 metastases Met1 (which
recruits eEPCs) and Met2 (which does not) were
stained with anti-VEGF antibody.
I–K: Both tumor cells and homed eEPCs express
VEGF. LLC cells were injected into the tail vein
of C57/BL/6 mice. Fourteen days later, eEPCs ex-
pressing EGFP were given twice spaced 3 days
apart. Two days after the second eEPC injection,
lungs were retrieved and sectioned. Blood ves-
sels were detected by anti-CD31 antibody (I),
eEPCs by anti-EGFP antibody (J), and VEGF-pro-
ducing cells by anti-VEGF antibody (K). A poorly
vascularized metastasis (I) recruits many eEPCs
(J) and stains positive for VEGF in most of its ex-
panse (K), including areas that stained positive
for EGFP in J.
L: Hypoxia upregulates VEGF mRNA and protein
in eEPCs. eEPCs were subjected to normoxia or
hypoxia for 6 hr. VEGF mRNA was detected by
RT-PCR with aldolase used as control. VEGF pro-
tein was immunoprecipitated and detected by
Western blotting.
M–O: Liver and kidney LM8 metastases express
less VEGF than lung metastases. Five metastases each in the lung, liver, and kidneys from two mice were stained for VEGF by immunohistochemistry.
Representative staining of metastases in the lung (M), liver (N), and kidneys (O) are shown.
Scale bars represent 200 m (A–C, G, H, M–O), 150 m (D–F), and 100 m (I–K).
eEPCs were predominantly found in poorly perfused metastases We extended our investigation to smaller LM8 and LLC
metastases using immunohistochemistry. Analyzing 14 LM8as revealed by i.v. premortem HPA-FITC-lectin injection (Figures
4A–4C). The hypoperfused metastases were also hypovascu- metastases in 3 C3H mice and 15 LLC metastases in 3 C57/
BL/6 mice, we confirmed that eEPCs, detected by anti-EGFPlarized, as was determined by postmortem staining for collagen
IV that is localized in the endothelial basal membrane of blood antibody, were preferentially found in metastases with de-
creased vascularity in both tumor models, as visualized by anti-vessels (Figures 4D–4F). There was no difference in the ratio of
well-vascularized to poorly vascularized metastases between CD31 antibody staining (Figures 4I and 4J). Surprisingly, we
found that in some of these smaller metastases, VEGF expres-eEPC-injected and noninjected tumor-bearing mice, indicating
that recruited eEPCs did not block blood flow in the metastases. sion colocalized not only with tumor cells but also with eEPCs
(Figure 4K). In vitro, eEPCs express low levels of VEGF in nor-Instead, these observations indicated that eEPCs preferentially
home to those metastases where decreased vascularity has led moxic conditions but upregulate both VEGF mRNA and protein
under hypoxic conditions (Figure 4L). These data indicate thatto decreased perfusion. Further analysis revealed that poorly
vascularized subpleural metastases recruiting eEPCs in their eEPCs might home preferentially to hypovascular metastases
suffering from hypoxia, which then causes upregulation of VEGFperiphery stained heavily for VEGF in their central areas,
whereas nonrecruiting metastases did not (Figures 4G and 4H). in tumor cells and recruited eEPCs.
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Figure 6. eEPCs incorporate long-term into tumor vessels
14–17 days after tail vein injection of DiI-labeled eEPCs into mice bearing
Figure 5. eEPCs home preferentially to hypoxic metastases LLC metastases, the lungs were examined by fluorescence and light micros-
Two days after tail vein injection of 4  105 DiI-labeled eEPCs into mice copy. Tumor vessels were stained with FITC-labeled Isolectin B4.
bearing LLC metastases, animals were injected premortem with the hyp- A: eEPCs (red) have homed predominantly to the periphery of a large
oxia-sensitive compound pimonidazol. Bound pimonidazol was visualized metastasis. The insert shows the H&E stain of the same area.
postmortem by immunofluorescence detection using an anti-pimonidazol B and C: Larger magnification corresponding to the boxed area in A. A
antibody, while eEPCs were detected by DiI fluorescence. number of eEPCs (red) have incorporated (yellow and orange) into tumor
A–C: A hypoxic metastasis recruits many eEPCs in the tumor tissue adjacent vessels (green).
to the hypoxic area. C: H&E stain of B.
D–F: A normoxic metastasis recruits few eEPCs. D–F: eEPCs incorporated also in blood vessels closer to the tumor’s center.
A and D are H&E stainings. Scale bars represent 200 m. D: Endothelial cells (green) stained with FITC-labeled Isolectin B4.
E: DiI-labeled eEPCs (red) in the area corresponding to D.
F: Overlay of D and E shows that eEPCs have incorporated (orange and
yellow) into tumor vessels (green).
Scale bars represent 200 m (A), 50 m (B and C), and 20 m (D–F).To test this notion, we determined the hypoxia levels in
tumor tissue by premortem injection of pimonidazol (which binds
to hypoxic tissue only) followed by immunofluorescence detec-
tion using an anti-pimonidazol antibody. Hypoxic metastases eEPCs to home to, integrate into, and proliferate within the
typically recruited many eEPCs around their hypoxic areas (Fig-
metastases before triggering their death. For this purpose, we
ures 5A–5C). In contrast, metastases that were negative for
stably transfected eEPCs with the yeast cytosine deaminasepimonidazol staining and not hypoxic recruited only very few
(CD) gene fused to uracil phosphoribosyl transferase (UPRT,eEPCs (Figures 5D–5F).
which shortcuts rate-limiting enzymatic steps). The fusion gene
acts as a strong catalyst converting the harmless prodrugeEPCs incorporate long-term into tumor vessels
5-fluorocytosine (5-FC) to the cytotoxic compound 5-fluoro-To determine if eEPCs contribute long-term to tumor vessel
uracil (5-FU) (Chung-Faye et al., 2001), a drug widely used information, DiI-labeled eEPCs were injected into the tail vein of
clinical practice. 5-FU diffuses into the interstitial space and ismice bearing LLC metastases. Analysis 14–17 days later
taken up by surrounding cells, thus exerting a strong bystandershowed that eEPCs had integrated into 1%–5% of the tumor
cytotoxic effect (Huber et al., 1994).vessels of a given metastasis and that the majority of eEPCs
eEPCs carrying the fusion gene (eEPC-CD), but not eEPCswere localized in the tumor tissue proper (Figure 6). In the LM8
containing the empty control vector, were effectively killed bymodel, we calculated that 4%–7% of tumor blood vessels in
5-FC concentrations achievable in vivo (Figure 7A). 5-FC-medi-the recruiting lung metastases contained eEPCs at 10 days after
ated cytotoxic effects were at maximum level after 5 days, wheneEPC injection (Figures 4C and 4F and data not shown).
near-complete cell death occurred (Figure 7B). Since eEPCs
were located predominantly within tumor tissue proper, we firstEffective target and bystander killing
determined the bystander cytotoxic effect of eEPC-CD on LM8by CD/5-FC in eEPCs
osteosarcoma cells. Mixtures of eEPCs and LM8 cells wereTo target lung metastases, we chose a suicide gene system
because it allows for inducible cell death, giving time for the treated with 5-FC. Cell survival less than the percentage of LM8
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Figure 7. Effective target and bystander killing by
CD/5-FC in eEPCs
A: eEPC-CD are killed by 5-FC depending on
dose. eEPC-CD or eEPC-pClneo (empty vector
control) cells were treated for 5 days with 5-FC
in doses as indicated.
B: Killing of eEPC-CD by 5-FC is protracted. eEPC-
CD/UPRT or eEPC-pClneo cells were exposed to
500 M 5-FC for the time indicated.
C: eEPC-CD with 5-FC exert a bystander effect
on tumor cells. Mixtures of eEPC-CD cells with
LM8 cells in the ratios indicated were treated
with medium alone (control) or with 1 mM 5-FC
for 5 days.
D: eEPC-CD with 5-FC exert a bystander effect
on microvascular endothelial cells. Mixtures of
eEPCs with bEnd5 cells in the ratios indicated
were treated with medium alone (control) or
with 1 mM 5-FC for 5 days. In all cases, survival
was measured by the MTT test. Results are means
of quadruplicates and are expressed as the per-
centage of untreated controls. Similar results
were obtained in three independent experi-
ments.
cells put into the assay denotes bystander killing. For instance, eEPC-CD with 5-FC eradicate
hypovascular metastaseswe measured that cell survival in a mixture containing 6.25%
In the mice that had received eEPC-CD and 5-FC, the metasta-eEPC-CD was just 60% (instead of the 93.75% expected if only
ses at the time of death were strikingly fewer than in the controleEPC-CD were killed), demonstrating a bystander effect (Figure
untreated mice (Figures 8B and 8D). The remaining metastases7C). In parallel experiments, we investigated the bystander ef-
that escaped treatment were highly vascularized (Figures 8Dfect of eEPC-CD on the mouse microvascular endothelial cell
and 8E) as compared to control untreated animals where theline bEnd5 that served as a surrogate for tumor endothelial
majority of the metastases were poorly vascularized (Figurescells. Similar to the effect on tumor cells, eEPC-CD exerted a
8B and 8C). This is in line with the finding that eEPCs homebystander cytotoxic effect on bEnd5 cells (Figure 7D).
preferentially to less vascularized metastases and is consistent
with the notion that these metastases are eradicated followingeEPC-CD with 5-FC prolong life of mice
5-FC administration, leaving only the more vascularized metas-with lung metastases
tases to grow further.We then investigated the effectiveness of eEPC-CD to kill tumor
cells in vivo. Knowing that eEPCs injected into the tail vein home
Discussionpredominantly to metastases in the lung, we selected LLC as
the tumor metastasis model. Injection of the tumor cells into
In cancer patients with no wounds or uterine cycling, neovascu-
the tail vein led to formation of numerous lung metastases in
logenesis is restricted to growing tumor masses, and therefore
each mouse, creating a hard-to-treat experimental system. Mice recruitment of endothelial progenitors promises to be specific to
with established multiple lung metastases lived significantly the tumor. Furthermore, since neovasculogenesis is a universal
longer when eEPC-CD were given by tail vein injection followed feature of most tumor types, exploiting it to recruit therapeutic
by systemic 5-FC administration (Figure 8A). Interestingly, me- EPCs offers the potential of targeting tumors irrespectively of
tastases-bearing mice that received eEPC-CD without 5-FC their antigenic and genetic make-up. Genetically modified endo-
lived shorter. Because eEPCs injected into mice without metas- thelial progenitor cells have been used successfully for this
tases did not shorten survival, the decreased survival in tumor- purpose (Gomez-Navarro et al., 2000; Davidoff et al., 2001;
bearing mice cannot be attributed to a toxic effect of the eEPC- Ferrari et al., 2003; De Palma et al., 2003). Differentiated endo-
CD, suggesting instead that eEPC-CD without 5-FC treatment thelial cells isolated from minced lungs or from umbilical veins
increased tumor growth. have also been employed for experimental tumor therapy (Ojeifo
Similar results were also obtained using LM8 osteosarcoma et al., 2001; Rancourt et al., 1998).
cells in C3H mice (data not shown). Survival rates were lower In this study, we have used mouse embryonic endothelial
as compared to the LLC experiments because of metastases progenitor cells for systemic cancer therapy for the first time.
growing also in liver and kidneys, organs that were not efficiently eEPCs can be easily propagated and genetically manipulated
reached by eEPC-CD injected into the tail vein. in culture, providing an unlimited source of cells with desired
The surviving control mice without tumor implantation that characteristics. eEPCs do not express MHC I antigens, are not
received eEPCs i.v. were analyzed 3 months later. Inspection of susceptible to lysis by nonactivated NK cells, and survive and
participate in tumor vessel formation in nonsyngeneic mice.organs did not reveal visible toxic effects or embryonic tumors.
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Thus, eEPCs from MHC-incompatible donors may, at least ini-
tially, be protected against cytotoxic T cells and NK cells after
in vivo administration. This raises hopes for future engineering
of EPCs for application as universal cellular vehicles indepen-
dent of host/donor compatibility.
To further evaluate the therapeutic value of eEPCs, we thor-
oughly analyzed their biodistribution into normal organs and
scrutinized transplanted mice for possible side effects. After tail
vein injection into mice without tumors, eEPCs were seques-
tered at low density in the lung, spleen, and to a lesser extent
the liver. The number of eEPCs sequestered in organs de-
creased with time. In this respect, eEPCs follow the fate of most
cells injected i.v. (Pabst et al., 1987; Brown et al., 1995). Given
the propensity of embryonic stem cells to form teratocarcino-
mas, it is important to note that eEPCs did not form tumors
up to 3 months after subcutaneous or i.v. transplantation. The
maturity of eEPCs as compared to embryonic stem cells may
account for this. The low numbers of eEPCs found in the organs
did not lead to toxic effects. This is further documented by the
fact that survival rates were not affected in tumor-free control
mice that received eEPC-CD or eEPC-CD and 5-FC (all animals,
13 and 14 mice, respectively, survived and showed no adverse
effects).
Homing of eEPCs to lung tumors was very efficient: after
two consecutive i.v. injections, 77% and 90% of all lung tumor
nodules were targeted in the nonsyngeneic LM8 osteosarcoma
and the LLC syngeneic metastasis models, respectively. Also,
while eEPCs were sequestered in the healthy lung and were
cleared over time if no metastases were present, eEPCs homed
Figure 8. eEPC-CD engraftment coupled to 5-FC treatment prolongs life of to and remained in hypovascular metastases. In both modelsmice with LLC pulmonary metastases by eradicating hypovascular tumors
of predominant lung tumors described here, the large numbers
A: 10- to 12-week-old male C57/BL/6 mice were injected via the tail vein
of eEPCs found in the lung metastases could be attributed towith 5  105 LLC cells on day 0. After metastases were established, mice
the combined effects of the high metastasis density in the lungwere given the first of two i.v. injections of 4  105 eEPC-CD cells spaced
48 hr apart. One day after the last inoculation of eEPC-CD, mice received and the fact that the eEPCs reach this organ first. Therefore,
12.5 mg 5-FC in 600 l PBS i.p. twice daily for 5 days. A second cycle of this approach might be best suited for the treatment of lung
eEPC-CD followed by 5-FC was started on day 16. The treatment group tumors. Targeting tumors in other organs may require injecting(green line) received the therapy described above. Control groups re-
eEPCs into the appropriate afferent vessels. In addition, liverceived LLC cells and PBS (blue line), LLC cells and 5-FC (black line), LLC
and kidney metastases in the LM8 model expressed less VEGFcells and eEPC-CD and PBS (red line), eEPC-CD and PBS (pink line), and
eEPC-CD and 5-FC (brown line). Kaplan-Meier survival curves show a pro- than lung metastases (Figures 4M–4O), suggesting that they
longed survival time of the metastasis-bearing mice treated with eEPC-CD were less hypoxic and thus less likely to recruit eEPCs.
and 5-FC (green line) compared to the metastasis-bearing control groups
This degree of homing is remarkable considering that it wasthat did not receive eEPC-CD (blue and black lines; p  0.05). Tumor-
achieved without prior bone marrow transplantation. Postirradi-bearing mice that received eEPC-CD but no 5-FC (red line) survived shorter
compared to the control groups (blue and black lines; p  0.05). All non- ation bone marrow transplantation biases toward homing of
tumor-bearing mice that had received eEPC-CDs survived (pink and brown exogenous EPCs by decreasing competition from endogenous
lines). The numbers of animals (n) in each group are indicated. EPCs (De Palma et al., 2003), by establishing a continuousB: Representative lung from the control group that received LLC cells and
source of bone marrow-derived exogenous EPCs, and byPBS only (blue line in A). Most of the metastases show only slight red color-
upregulating tumor angiogenesis (Sonveaux et al., 2003). More-ation, indicating poor vascularization (arrows).
C: Histological analysis using an anti-CD31 antibody of lung metastases over, the need of lethal or sublethal myeloablation would se-
shown in B indicates that they contain few blood vessels. verely limit the applicability of EPCs in the clinical setting. The
D: Representative lung from the treatment group (eEPC-CD and 5-FC, green
independence of homing from bone marrow transplantation mayline in A). Metastases in the treatment group (arrows) are fewer but larger
be a major advantage of embryonic EPCs as compared to adultand well vascularized.
E: Surviving metastases are well vascularized. Histological analysis of a repre- counterparts.
sentative metastasis that escaped the cytotoxic effect of eEPC-CD shows eEPCs also exhibited a remarkable specificity for metasta-
numerous vessels. Endothelial cells were stained using an antibody against ses. 5 to 7 days after injection, eEPCs were found in low numbersCD31. In both cases lungs were procured at the time when the mice ap-
in normal lung tissue, but they congregated densely in the me-peared moribund. Scale bars represent 100 m.
tastases. The preferential homing of eEPCs into lung metastases
does not reflect an unspecific sequestration into the lung. First,
there was long-term accumulation of eEPCs at the metastases
with scant eEPCs in the normal lung tissue. If homing of eEPCs
was a passive event, one would expect a homogeneous distribu-
tion of eEPCs throughout normal and tumor tissue and a clearing
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of eEPCs with time. Second, in contrast to eEPCs, mouse fibro- be one of their major advantages because hypoxic tumors are
blasts that have similar size to eEPCs did not show tumor- notoriously resistant to chemotherapy, radiation, and antiangio-
specific accumulation after i.v. injection. In support of these genic therapies given as single modalities. Second, within the
findings, we have previously shown using intravital microscopy time frame of the treatment experiments, the eEPCs were pre-
that homing follows an active interaction between eEPCs and dominantly found within the tumor tissue and not the tumor
tumor vasculature with E- and P-selectin expressed on tumor vasculature. This is consistent with recent findings that undiffer-
cells mediating the initial eEPC recruitment step (Vajkoczy et entiated eEPCs deposited around subcutaneous tumors form
al., 2003). We did not observe in these experiments that injected clusters within the tumor, while eEPCs differentiated in vitro
eEPCs obstructed tumor vessels. It is possible that the tumor incorporate into tumor vessels after the same procedure (Yur-
microenvironment enhances survival and proliferation of se- ugi-Kobayashi et al., 2003). Our tumor/eEPCs co-implantation
questered eEPCs and thus contributes to eEPC accumulation experiments also show that eEPCs effectively incorporate into
within the metastases. tumor vasculature only after prolonged time periods (3–4
The lung metastases-bearing mice that received eEPCs sur- weeks). Therefore, while immature eEPCs would be able to exert
vived a shorter time, suggesting an unwanted paracrine effect a bystander effect on tumor cells, they might kill only a few
of eEPCs on tumor or tumor endothelial cells possibly due to tumor endothelial cells. Third, homed eEPCs may enhance tu-
production of VEGF or other growth factors. Consistent with mor growth until the suicide gene system is triggered. Tumor
this hypothesis, we find that eEPCs preferentially accumulate growth may be enhanced by increased vascularity due to eEPCs
in the vicinity of hypoxic areas in the tumor and that hypoxia incorporating in tumor vessels. However, the number of eEPC-
strongly upregulates VEGF expression in eEPCs. VEGF in turn containing tumor vessels was too low to fully account for the
can increase angiogenesis and also exert a proliferative and observed lower survival rates of eEPC-injected tumor-bearing
antiapoptotic effect both on tumor and tumor endothelial cells mice. Trophic factors produced by the large number of homed
(Masood et al., 2001; Bachelder et al., 2001). eEPCs may increase tumor growth. The VEGF produced in the
Intravenously injected eEPCs contributed long-term to tu- homed eEPCs may augment angiogenesis and also exert a
mor vasculature. The number of eEPC-containing vessels varied proliferative and antiapoptotic effect both on tumor and tumor
from metastasis to metastasis between 1% and 5% in the LLC endothelial cells (Shweiki et al., 1992; Masood et al., 2001;
model and between 4% and 7% in the LM8 model. Although Bachelder et al., 2001). Fourth, suicide gene systems need time
many eEPCs had incorporated into tumor vessels, the majority to kill bystander cells, because they first have to convert the
of eEPCs were still found inside the tumor tissue. However, the
prodrug to a cytotoxic compound. The CD/UPRT enzymatic
number of eEPCs found in blood vessels rises dramatically if
system starts to kill bystander cells in significant numbers only
the eEPCs and the tumor cells are co-implanted simultaneously
after 3 days, a period long enough for the rapidly growing tumorsin subcutaneous locations. This observation reflects recent
to become too large to eradicate. Lastly, any cellular vehiclefindings using ES-derived EPCs in tumor-induced angiogenesis
with a suicide gene system has the inherent disadvantage ofmodels (Marchetti et al., 2002; Yurugi-Kobayashi et al., 2003).
destroying itself by the very same mechanism by which it killsIn these studies, no homing to tumors was detected, but ES-
tumor cells. Further studies will need to address these points.derived EPCs significantly contributed to tumor blood vessels
In conclusion, intravenously delivered therapeutic embry-if co-implanted with tumor cells. The eEPCs used in this study,
onic endothelial progenitor cells target lung metastases, evenisolated from day 7.5 mouse embryos, show efficient homing
in MHC I disparate hosts and do not form carcinomas. eEPCsto angiogenic sites, suggesting a richer expression profile of
show limited and transient engraftment efficiency in normal tis-cell-cell interaction receptors and chemotactic receptors. If
sues, whereas they home and survive long-term within metasta-eEPCs are administered i.v. in conditions of aggressive local
ses, particularly if these are hypovascular and hypoxic. Furtherangiogenesis, they probably cannot compete effectively with
investigations will have to assess whether homing-associatedthe local sprouting endothelium as well as with circulating en-
molecules of tumor or stroma are differentially expressed indogenous EPCs. Therefore, their intrinsic ability to form de novo
recruiting and nonrecruiting metastases and whether these dif-blood vessels in situ, as in the embryo, might be better mani-
ferences can account for preferential recruitment. Future experi-fested if eEPCs are present at early stages during neoangiogen-
ments will also aim to increase the efficacy of therapeutic eEPCsesis. In our study, this limitation was not critical for therapeutic
in combination regimes designed to target well-vascularizedefficacy. Although the percentage of tumor blood vessels
metastases by chemo- or anti-angiogenic therapy in parallel.formed by eEPCs given i.v. was relatively low, the specific and
efficient homing to metastases as opposed to normal tissues
Experimental procedurescould be exploited for attacking the tumor.
To target metastases, we armed the eEPCs with the suicide Cell culture
gene CD/UPRT. eEPCs expressing CD/UPRT exhibited a sig- eEPCs were isolated from mouse embryos at day 7.5 to 7.8 of development
nificant bystander cytotoxic effect in vitro on both endothelial and propagated as primary cell lines as described (Hatzopoulos et al., 1998).
The murine osteosarcoma cell line LM8 was grown in MEM  mediumand tumor cells. Given systemically and followed by the prodrug
supplemented with 10% heat-inactivated fetal calf serum (FCS). Lewis lung5-FC, eEPCs significantly prolonged the lifetime of mice with
carcinoma cells 3LL-D122 were grown in DMEM with 1 mM sodium pyruvatemultiple established lung metastases. However, prolongation
supplemented with 10% FCS. bEnd5 cells were maintained in DMEM me-of survival was moderate and no cures were achieved. Several
dium supplemented with 10% FCS and 5 M 	-mercaptoethanol. For fibro-
reasons may account for this result. First, eEPCs homed poorly blast cell culture, skin from C57BL/6J mice was minced and placed in culture
to well-vascularized metastases, which subsequently continued dishes with DMEM, 15% FCS, and 5 M 	-mercaptoethanol. Outgrowing
to grow and killed the mice. On the other hand, the eEPCs’ adherent cells were passaged repeatedly. All culture media were supple-
mented with 2 mM glutamine, 2 mM nonessential amino acids, 100 U/mlability to home to poorly vascularized, hypoxic metastases may
CANCER CELL : MAY 2004 485
A R T I C L E
penicillin, and 100 g/ml streptomycin. Tissue culture materials were ob- Fourteen days later, the mice were given either one i.v. injection of 4  105
eEPC-EGFP cells or two such i.v. injections spaced 3 days apart. The micetained from Life Technologies Inc. (Eggenstein, Germany).
were euthanized 5 to 7 days later. Tumor-bearing mice not transplanted
with eEPC-EGFP cells (n  5), as well as tumor-free mice that received thePlasmid constructs
same number of eEPC-EGFP cells as the experimental groups (n  5), wereThe pCIneo-CD/UPRT vector expressing the suicide gene was obtained
used as controls. Organs were removed and processed for immunohisto-from Transgene S.A. (Strasbourg, France). The vector pCI-neo (Promega,
chemical analysis as described below. To compare unspecific sequestrationMannheim, Germany) was used as empty vector control. The pPGK-EGFP
of cells with specific homing of eEPCs, 2 C57/BL/6 mice carrying establishedplasmid was generated from pPGK-neo (PGK, phosphoglycerate kinase
LLC pulmonary metastases were injected i.v. with 4  105 DiI-labeled skinpromoter) by substituting the neomycin resistance gene with EGFP (Clon-
fibroblasts from C57/BL/6 mice, while 3 tumor-bearing mice received thetech, Heidelberg, Germany).
same number of DiI-labeled eEPCs. Lungs were procured 2 days after cell
injection, snap-frozen, cryosectioned, and microscopically examined for DiI-Cell transfection
fluorescence. To determine the long-term fate of eEPCs in tumors afterEither pCIneo-CD/UPRT, pCI-neo, or pPGK-EGFP were transfected into
homing, mice were injected with 4  105 DiI-labeled eEPCs per mouse viaeEPCs using Lipofect according to the manufacturer’s instructions (Stra-
tail vein 9 days after LLC (n  5) or LM8 (n  3) injection. Organs weretagene, La Jolla, CA), and stably transfected cells were selected yielding
removed 14 to 17 days (LLC) or 10 days (LM8) after eEPC injection andeEPC-CD, eEPC-mock, and eEPC-EGFP, respectively.
snap frozen for further analysis. Tumor blood vessels were visualized after
lectin or collagen IV staining as described below.Flow cytometry
Suspended eEPCs, NIH 3T3 cells, T cells, and primary mast cells (kindly
Immunofluorescence microscopy and lectin bindingprovided by Dr. Hu¨ltner, GSF, Germany) were incubated with 10 g/ml rat
Serial frozen sections were examined. DiI-labeled eEPCs were detectedpan anti-mouse MHC I antibody (TIB 126; ATCC, Manassas, VA) or purified
without further manipulations. For VEGF detection, we used 2 g/ml rabbitrat IgG1 (BD Pharmingen, San Diego, CA) in FACS buffer (1% BSA and
anti-VEGF antibody (Santa Cruz Biotechnology, Santa Cruz, CA), followed0.1% NaN3 in phosphate-buffered saline [PBS]) for 30 min on ice. Subse-
by 2g/ml goat-anti-rabbit Cy3-conjugated IgG (Dianova). The anti-collagenquently, eEPCs were washed twice and incubated with 10 g/ml phycoer-
IV rabbit antiserum was a kind gift of Dr. R. Timpl (MPI, Germany) and wasythrin (PE)-conjugated anti-rat IgG (Dianova, Hamburg, Germany) in FACS
used in 1:600 dilution followed by 3 g/ml goat-anti-rabbit FITC-conjugatedbuffer and 5% mouse serum for 30 min. Analysis was performed on a
IgG (Dianova). Perfused blood vessels were visualized by injection of 200FACSCalibur flow cytometer using CellQuest software (Becton Dickinson,
l of 550 g/ml Helix Pomatia lectin (HPA) coupled with FITC (SIGMA,San Jose, CA).
Steinheim, Germany) via the tail vein 5 min prior to organ isolation. FITC-
labeled GSL I-isolectin B4 (Vector Laboratories, Burlingame, CA) at a concen-NK cell cytotoxicity assays
tration of 150g/ml was used to detect mature endothelial cells. HematoxylinNK cell cytotoxicity assays were carried out as described (Chan et al., 2001).
or hematoxylin/eosin (H&E) were used for subsequent counterstaining.Briefly, splenocytes were depleted of CD4 and CD8 cells by complement
lysis and used in a standard 51Cr-release assay against YAC-1 (Kiessling et
Immunohistochemistryal., 1975), RMA/S (Ljunggren and Karre, 1985), and T15B (an eEPC line)
Organs were fixed with buffered 3.7% formaldehyde solution, embedded incells as targets. Target cells were labeled with 51Cr (100 mCi; Amersham
paraffin, and serially cut into 5 m thick sections. Deparaffinized and rehy-Biosciences, Freiburg, Germany) for 1 hr at 37
C. Cells were washed and
drated sections were either microwaved in citrate acid buffer (0.01 M, pHincubated with NK effectors at effector (E):target (T) ratios as indicated. After
6.0) or digested with proteinase K (DAKO, Hamburg, Germany) to demask4 hr at 37
C, the cell-free supernatants were transferred to a  counter to
antigens. Endogenous peroxidase was blocked with 3% H2O2, endogenousdetermine 51Cr release. Spontaneous cell lysis and maximum cell lysis were
biotin activity by the biotin/avidin blocking system (DAKO), and unspecificmeasured using 104 cells in medium alone and in 1% Triton X-100, respec-
antibody binding by 1% bovine serum albumin (BSA, Serva, Heidelberg,tively. Percentage of specific lysis was calculated with the formula: % sample
Germany) and 10% normal goat serum (DAKO). Slides were incubated over-specific lysis [(sample counts spontaneous counts)/(maximum counts
night at 4
C with rabbit anti-EGFP (5g/ml in 0.1% Triton; Molecular Probes),spontaneous counts)]  100%.
rabbit anti-VEGF (2 g/ml, Santa Cruz), and biotinylated rat anti-CD31 (6
g/ml; DPC Biermann, Bad Nauheim, Germany). Peroxidase-conjugatedAssessment of biodistribution
goat anti-rabbit IgG (DAKO) was used as secondary antibody to detect EGFP
The chelating ligand p-SCN-mx-DTPA (diethylenetriaminepenta-acetic acid)
and VEGF, while peroxidase-conjugated avidin/biotin complexes (DAKO)
was coupled to LDL, creating a thiourea bond between the reactive SCN
were employed for the detection of CD31.
group of the chelator and a primary amine of the protein (in HEPES buffer
[pH 7.9]). After purification (using size exclusion HPLC) and buffer exchange Hypoxia detection
(acetate buffer [pH 5.0]), the labeling was performed with 60 MBq of 111In. To detect tumor hypoxia in vivo, we injected pimonidazol (Hypoxyprobe-1,
30 MBq of the product 111In-DTPA-LDL was isolated using size exclusion Chemicon International, Temecula, CA) at a dose of 60 mg/kg body weight
HPLC (purity  98%). eEPCs were incubated with 111In-DTPA-LDL for 4 hr via tail vein into mice 1 hr prior to organ isolation. Serial frozen sections
at 37
C in serum-free medium. Cells (111In-LDL-eEPCs) were washed and were incubated with anti-pimonidazol Hypoxyprobe-1 Mab1 (Chemicon) di-
resuspended in serum-free medium. 6- to 8-week-old C3H male mice re- luted 1:50 followed by RPE-conjugated goat anti-mouse IgG1 F(ab’)2 (South-
ceived 4  105 111In-LDL-eEPCs via tail vein injection. Mice were killed on ern Biotech, Birmingham, AL).
day 2 (n  3) and on day 5 (n  3) after eEPC injection. Blood was aspirated
by intracardiac puncture and the femurs and solid organs were procured. VEGF detection
Samples were analyzed using a  counter. Samples obtained from nonin- eEPCs were cultured under normoxic (21% O2) and hypoxic (2% O2) condi-
jected mice served as background control. To assess the biodistribution of tions for 1 to 24 hr. The protocol for detection of VEGF and aldolase tran-
eEPCs into solid organs by immunohistochemistry and into bone marrow scripts by RT-PCR has been described (Vajkoczy et al., 2003). VEGF protein
by FACS analysis, 4  105 eEPC-EGFP cells were tail vein injected into C3H was analyzed by immunoprecipitation followed by Western blotting using
mice (n  3). Noninjected mice (n  3) were used as control. Solid organs standard protocols.
were procured 2 days after the eEPC injection and analyzed using an anti-
EGFP antibody for immunohistochemistry as described below. Bone marrow Determination of cell death in vitro
devoid of erythrocytes was analyzed by FACS analysis measuring forward Cell death was measured by the MTT [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphe-
scatter and EGFP fluorescence. nyl-2H-tetrazolium bromide] assay as described (Beltinger et al., 2002).
Assessment of homing Bystander effect assays
Either LM8 cells (2  105 per mouse) or LLC-D122 cells (5  105 per mouse) eEPC-CD cells were mixed with LM8 or with bEnd5 cells in ratios of 0%,
1.6%, 3.2%, 6.3%, 12.5%, 25%, 50%, and 100%. The mixtures were platedwere injected into the tail vein of 8 C3H and 5 C57/BL/6 mice, respectively.
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Davidoff, A.M., Ng, C.Y., Brown, P., Leary, M.A., Spurbeck, W.W., Zhou, J.,in 96-well plates at a density of 1  103 per well and allowed to attach
Horwitz, E., Vanin, E.F., and Nienhuis, A.W. (2001). Bone marrow-derivedovernight. Cells were then treated with medium alone (control) or with 1 mM
cells contribute to tumor neovasculature and, when modified to express an5-FC for 5 days and cell death was measured using the MTT assay.
angiogenesis inhibitor, can restrict tumor growth in mice. Clin. Cancer Res.
7, 2870–2879.In vivo survival experiments
10- to 12-week-old male C57/BL/6 mice were injected intravenously with De Palma, M., Venneri, M.A., Roca, C., and Naldini, L. (2003). Targeting
5  105 3LL-D122 cells and randomized to 4 groups (n  15 per group). exogenous genes to tumor angiogenesis by transplantation of genetically
On day 8, two groups of mice were given the first of two intravenous injections modified hematopoietic stem cells. Nat. Med. 9, 789–795.
of 4  105 eEPC-CD cells in 400 l PBS spaced 48 hr apart. Starting 2 days
Ferrari, N., Glod, J., Lee, J., Kobiler, D., and Fine, H.A. (2003). Bone marrow-after the last inoculation of eEPC-CD, either 12.5 mg 5-FC (SIGMA) in 600
derived, endothelial progenitor-like cells as angiogenesis-selective gene-l PBS or the same volume of PBS were injected intraperitoneally twice
targeting vectors. Gene Ther. 10, 647–656.daily for 5 days. This cycle of eEPC-CD administration followed by 5-FC
injections was repeated once. Two additional groups of mice not trans- Gehling, U.M., Ergun, S., Schumacher, U., Wagener, C., Pantel, K., Otte,
planted with 3LL-D122 tumors received eEPC-CD cells i.v. as above, fol- M., Schuch, G., Schafhausen, P., Mende, T., Kilic, N., et al. (2000). In vitro
lowed by administration of 5-FC or PBS for 5 days (n  15). Tumor-bearing differentiation of endothelial cells from AC133-positive progenitor cells.
mice were monitored daily and sacrificed when appearing moribund as Blood 95, 3106–3112.
determined by a blinded observer. Surviving mice that received only eEPC-
Gomez-Navarro, J., Contreras, J.L., Arafat, W., Jiang, X.L., Krisky, D., Olig-
CD cells were killed 3 months later. Organs were removed and processed
ino, T., Marconi, P., Hubbard, B., Glorioso, J.C., Curiel, D.T., and Thomas,
for histological analysis as described above. All animal work was performed J.M. (2000). Genetically modified CD34 cells as cellular vehicles for gene
in accordance with state guidelines for animal care and use. delivery into areas of angiogenesis in a rhesus model. Gene Ther. 7, 43–52.
Hanahan, D., and Folkman, J. (1996). Patterns and emerging mechanismsStatistical analysis
of the angiogenic switch during tumorigenesis. Cell 86, 353–364.Survival data were analyzed by Kaplan-Meier estimator analysis and com-
pared using the Kruskal-Wallis Test for multiple comparisons and the Mann- Hatzopoulos, A.K., Folkman, J., Vasile, E., Eiselen, G.K., and Rosenberg,
Whitney Test for single comparisons. Values of p  0.05 were considered R.D. (1998). Isolation and characterization of endothelial progenitor cells
significant. from mouse embryos. Development 125, 1457–1468.
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